SEC Comment Letter 0000000000-23-007769 to HALOZYME THERAPEUTICS, INC. (HALO) (CIK 0001159036) (HALO)
HALOZYME THERAPEUTICS, INC. (HALO) (CIK 0001159036)
Date: July 21, 2023 · CIK: 0001159036 · Accession: 0000000000-23-007769
AI Filing Summary & Sentiment
File numbers found in text: 001-32335
Letter
United States securities and exchange commission logo July 21, 2023 Nicole LaBrosse Senior Vice President and Chief Financial Officer Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego, CA 92130 Re:Halozyme Therapeutics, Inc Form 10-K for the Fiscal Year Ended December 31, 2022 Filed February 21, 2023 File No. 001-32335 Dear Nicole LaBrosse: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
July 21, 2023
Nicole LaBrosse
Senior Vice President and Chief Financial Officer
Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego, CA 92130
Re:Halozyme Therapeutics, Inc
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed February 21, 2023
File No. 001-32335
Dear Nicole LaBrosse:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences